Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial by Karim, Quarraisha Abdool et al.
RESEARCH Open Access
Recruitment of high risk women for HIV prevention
trials: baseline HIV prevalence and sexual behavior
in the CAPRISA 004 tenofovir gel trial
Quarraisha Abdool Karim
1,2, Ayesha BM Kharsany
1*, Janet A Frohlich
1, Cheryl Baxter
1, Nonhlanhla Yende
1,
Leila E Mansoor
1, Koleka P Mlisana
1, Silvia Maarschalk
1, Natasha Arulappan
1, Anneke Grobler
1, Sengeziwe Sibeko
1,
Zaheen Omar
1, Tanuja N Gengiah
1, Mukelisiwe Mlotshwa
1, Natasha Samsunder
1, Salim S Abdool Karim
1,2
Abstract
Background: Young women in sub-Saharan Africa bear a disproportionate burden of HIV infection compared to
men but have limited options to reduce their HIV risk. Microbicides could fill an important HIV prevention gap for
sexually active women who are unable to successfully negotiate mutual monogamy or condom use.
Purpose: This paper describes the baseline sample characteristics in the CAPRISA 004 trial which assessed the
safety and effectiveness of the vaginal microbicide, 1% tenofovir gel for HIV prevention in South Africa.
Methods: This analysis assessed the baseline demographic, clinical and sexual behavior data of women screened
and enrolled into the trial. The characteristics were summarized using descriptive summary measures; expressed as
means and percent for categorical variables.
Results: HIV prevalence at screening was 25.8% [95% Confidence Interval (CI):23.9-27.7). Of the 889 eligibly enrolled
women who contributed follow-up data, rural participants recruited from a family planning (FP) clinic were
younger, more likely to be living apart from their regular partner, reported lower coital frequency, had lower
condom use (p < 0.001). In contrast, urban participants recruited from a sexually transmitted disease (STD) clinic
reported higher numbers of lifetime sexual partners, new partners in the last 30 days and receiving money in
exchange for sex (p < 0.001).
Conclusion: The populations selected provide suitable diverse target groups for HIV prevention intervention studies.
Trial registration: ClinicalTrials.gov: NCT 00441298
Background
It is estimated that sexual transmission accounts for 85%
of HIV infections and more than 50% of the global bur-
den of infection is in women [1,2]. The majority of HIV
infected women live in Sub-Saharan Africa and young
women in this region have a 3-6 fold higher burden of
HIV infection compared to men [1,3,4].
South Africa has the highest burden of prevalent and
incident HIV infections, with the province of KwaZulu-
Natal at the epicenter of the pandemic [5-10]. Pre-trial
cohort studies at the Centre for the AIDS Programme
of Research in South Africa (CAPRISA) Vulindlela and
eThekwini clinical research sites reported high HIV inci-
dence rates in young women aged 14-30 years utilizing
public sector family planning (FP) and sexually trans-
mitted diseases (STD) clinics [11].
The ability of women in these settings to function
within the current “ABC” (Abstinence, Be faithful, Con-
dom use) paradigm of HIV prevention is limited [12]
especially for those unable to be abstinent, negotiate
mutually faithful monogamy or condom use due to
complex structural, social, economic and political factors
and underscore the urgent need for women-initiated
HIV prevention options [13,14]. Therefore, the under-
standing of HIV risk behaviors within target populations
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the potential differential effects of an intervention on
reported behavior.
Topical microbicides offer an option for these women
to reduce their HIV risk and to date several classes of
products have undergone advanced clinical testing
[15-20]. These trials have provided important lessons for
the conduct of microbicide trials [21] and informed
design, product selection, and dosing strategy in the
CAPRISA Phase IIB trial which assessed the safety and
effectiveness of 1% tenofovir gel in preventing HIV
infection in women in KwaZulu-Natal, South Africa
(CAPRISA 004 trial). The CAPRISA 004 trial recently
demonstrated the groundbreaking result of an estimated
3 9 %r e d u c t i o ni nh e t e r o s e x u a l l yt r a n s m i t t e dH I Va n d
tenofovir gel (p = 0.017), a promising HIV prevention
biomedical intervention for women [22].
The purpose of this exploratory analysis was to assess
the baseline sample characteristics of the CAPRISA 004
trial participants to optimize recruitment for HIV pre-
vention trials.
Methods
Ethical approvals
The protocol for the primary study, informed consent
forms and study related materials were reviewed and
approved by the University of KwaZulu-Natal Biomedi-
cal Research Ethics Committee, Ref: E111/06, the Pro-
tection of Human Subject Committee in the Office of
International Research Ethics at FHI Ref: 9946, and the
South African Medicines Control Council (MCC), Ref:
20060835. The trial was registered with ClinicalTrials.
gov, number NCT 00441298.
Study procedures
The CAPRISA 004 trial was conducted between May
2007 and March 2010 in KwaZulu-Natal, South Africa
at the CAPRISA Vulindlela Clinical research site in
Vulindlela, a rural community 150 km west of Durban
(rural) and at the CAPRISA eThekwini Clinical research
site in the Durban city centre (urban).
At the rural site, volunteers were recruited from
among women attending the FP clinic from one of the
primary health care centre, adjacent to the CAPRISA
Vulindlela clinical research site [11,23], whilst at the
urban site volunteers were recruited from women
attending the STD clinic at the Prince Cyril Zulu Com-
municable Disease Centre adjacent to the CAPRISA
eThekwini clinical research site [11].
Participant screening, enrolment and randomization
procedures have previously been described in detail [22].
Briefly, volunteers at the study sites were provided with
study information in English and/or isiZulu and those
agreeing to continue with study participation were eligible
if they were 18 to 40 years of age, willing to provide writ-
ten informed consent for screening, agreed to provide ade-
quate locator information for study retention purposes,
agreed to adhere to study visit schedule, were sexually
active; defined as having had vaginal intercourse at least
twice within the last 30 days prior to screening, HIV nega-
tive, not pregnant, agreeable to be on a non-barrier form
of contraception, creatinine clearance of >50 ml/min using
the Cockcroft and Gault method [24] and no evidence
deep epithelial disruption on pelvic examination. Volun-
teers were excluded if they had plans to travel away from
the study site following enrolment, planned to relocate
away from the study site, planned to become pregnant,
planned to or were currently enrolled in any other study
of an investigational product or behavior modification
related to HIV prevention, had any known allergy to latex
or had an untreated sexually transmitted infection.
Through two screening visits volunteers were assessed
for eligibility, contraceptive needs, pregnancy, HIV in
the context of pre- and post-test counseling, renal func-
tion, physical and medical evaluations and for pre-exist-
ing deep epithelial disruption/genital ulceration by
speculum-aided pelvic examination.
Within 30 days of the first screening visit, returning
eligible volunteers proceeded with the enrolment and
specimen storage consents, completed study enrolment
procedures and were randomly assigned to receive either
1% tenofovir gel or the hydroxy-ethylcellulose (HEC)
placebo in a 1:1 ratio. Participants received an assigned
study gel in boxes of ten in quantities guided by the fre-
quency of coital activity. At the enrolment visit, trained
study staff collected demographic, behavioral, sexual and
reproductive health data using interviewer administered
standardized questionnaires. Detailed medical history
was collected; physical and clinical assessments were
completed. Blood was drawn for baseline safety assess-
ments, storage and retrospectively tested for Hepatitis B
and herpes simplex virus type 2 (HSV-2) antibodies.
Follow-up care
At screening volunteers identified as HIV positive were
referred to the PEPFAR-funded CAPRISA AIDS Treat-
ment (CAT) Programme operational at both the rural
and urban sites for free care, support and antiretroviral
treatment. Participants with window-period HIV infec-
tion at enrolment (i.e. sero-negative but with detectable
virus based on HIV-1 RNA PCR) [25] and those who
became HIV infected during follow-up were referred to
the CAPRISA 002 Acute HIV infection study for follow-
up counseling, care and support.
Statistical analysis and reporting
The demographic and behavioral characteristics at base-
line were summarized using descriptive summary
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(±SD)] and percent for categorical variables. Fisher’s
exact tests were used for the analysis of categorical data,
and unpaired t-tests or the Wilcoxon rank sum tests for
the analysis of continuous data. All analyses were per-
formed using two-sided tests. The SAS statistical pack-
age (version 9.1.3; Statistical Analysis Software, North
Carolina, USA) was used for analysis.
Results
Recruitment and eligibility
Participants were accrued over 19 months from May
2007 to January 2009. The total number of volunteers
screened, numbers and reasons for exclusion, and total
number of participants enrolled, randomized and
assigned to study arm by site is presented in figure 1.
Of the 2160 volunteers screened, 1110 (51.4%) were
from the FP clinic at the rural site and 1050 (48.6%)
from the STD clinic at the urban site. Of the 2079 parti-
cipants tested for HIV, HIV prevalence at screening was
25.8% [95% Confidence Interval (CI) 23.9-27.7]; and was
the most common reason for volunteer ineligibility. The
age specific HIV prevalence is presented in table 1. Of
the 1227 volunteer’s eligible for enrolment, a total of
142 (6.6%) did not return for their enrolment visit
resulting in a total of 1085 participants being enrolled
and randomized.
Following enrolment, 196 (18.0%) participants were
considered ineligible and excluded; 8 (6-FP rural and 2-
STD urban) participants were confirmed to be within the
window-period of HIV infection at enrolment; 185 parti-
c i p a n t sw e r ec o n s i d e r e dt ob ei n e l i g i b l ye n r o l l e da c c o r d -
ing to the protocol eligibility criteria as they had
participated in the last 12 months prior to enrolment (n
= 50) or were currently co-enrolled (n = 135) in a trial of
vaginally applied product related to HIV prevention [26],
one participant provided false identification and was sub-
sequently identified as being less than 18 years of age,
two participants did not have a post-randomization HIV
test that was required for endpoint ascertainment. The
independent data safety and monitoring board reviewed
the safety data for all ineligibly enrolled participants,
found no negative safety trends and agreed to the plans
for discontinuation of these participants [27]. The final
number of eligible enrolled participants was 889, 611
were enrolled at the rural site and 278 at the urban site.
A total of 445 participants were randomized to tenofovir
gel arm and 444 to the placebo gel arm.
Baseline Socio-demographic, Clinical and Sexual
Behavioral Characteristics
The baseline socio-demographic, clinical and sexual
behavioral characteristics are presented in table 2. Rural
participants recruited from the FP clinic were younger,
had lower mean parity and were more likely to be living
apart from their regular partner. In contrast, urban par-
ticipants recruited from the STD clinic were older, with
higher levels of education and income. With regard to
sexual behavior characteristics, rural FP participants had
a lower mean age of sexual debut, reported lower mean
number of sex acts in the past 7 and 30 days, were
more likely to be living separately from their regular
partner due to partner or self-employment options and
had lower condom use compared to their urban STD
counterparts. A higher proportion of urban STD partici-
pants reported having a new partner in the past 30 days,
having higher numbers of lifetime sexual partners and
having received money in exchange for sex compared to
the rural FP participants (all p < 0.001).
Overall, 29.1% of participants reported consistent male
condom use at baseline; 0.7% reported coerced sex and
1.9% reported transactional sex. About one in five
(20.1%) participants reported being aware that their sex
partner had other sex partners in the past 30 days and
only 2.1% reported that their partner had an HIV test in
the past 30 days. Although 29.5% of participants’
reported that their partner usually consumed alcohol
before sex, only 4.0% reported having consumed alcohol
before their last sex act. All the women reported enga-
ging in vaginal sex practice, with 4.7% also reporting
oral sex and <1% reporting anal sex.
About 2 in 5 participants (37.8%) reported at least one
genital symptom including symptoms of abnormal vagi-
nal discharge being the commonest in 32.4%, followed
by vaginal burning, pruritis, burning on and frequent
urination, genital ulceration, pain during sex and inter-
menstrual bleeding, with 7.6% reporting more than one
genital symptom. The prevalence of these genital symp-
toms was higher among urban STD (52.5%) compared
to rural FP participants (30.9%). Amongst urban STD
participants the proportion of women with genital
symptoms ranged from 56.9% in the 25 to 29 year age
group to 45.5% in the 35 to 40 year age group years,
whilst amongst rural FP participants, the proportion of
women with these symptoms ranged from 33.9% in the
25 to 29 year age group to 16.7% in the 35 to 40 year
age group. The overall prevalence of HSV-2 antibodies
at baseline was 51.4%; amongst rural FP participants it
was 47.6% compared to 59.6% among urban STD parti-
cipants (p = 0.001).
Discussion
The very different rural FP and urban STD participants
who comprise the CAPRISA 004 trial cohort has pro-
vided important safety and effectiveness information in
terms of varying coital frequency, frequency of gel use
and gel use in the presence or absence of sexually trans-
mitted infections [22].
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it is important to identify populations at highest risk of
acquiring HIV infection [21]. Data from multiple
sources confirm that KwaZulu-Natal, South Africa is at
the epicenter of the HIV pandemic [1,5,10,11,28]. In
mature, generalized hyper-endemic settings where HIV
prevalence is unprecedentedly high as in KwaZulu-
Natal, identifying most at-risk populations is a challenge
as it defies typical high HIV risk definitions applicable
in more concentrated and low prevalence settings.
Enrolled   
 N=620 
Enrolled  
N=465 
Screened  
N=1050 
Screened  
N=1110 
Urban  
(STD) 
Rural  
(FP) 
N=611 
Excluded for ineligibility based on 
pre-enrolment criteria (n=187)   
135 ineligible -co-enrolled   
50   ineligible  not  co-enrolled   
 2   Window-period HIV infection at  
       enrolment   
N=278 
Not enrolled (n=585)   
264 HIV positive 
33   Not  sexually  active   
27   Pregnancy  test  positive 
6   Planning to fall pregnant 
14   Planning to relocate 
24   Allergic to latex 
21   Not  using  contraceptives 
14   Unable to provide IC 
 2   Inadequate locator information 
21   Participant  unwilling   
 3   Not a sex worker 
21   Medical  condition 
36   Participated in other research 
10   Unable  to  attend  visits 
 2   Age 
 3   Not recruited from STI clinic 
 0   No ID book 
84   Did not return for enrolment 
Not enrolled (n=490)   
272 HIV positive 
99   Not  sexually  active   
9   Pregnancy  test  positive 
9   Planning to fall pregnant 
9   Planning to relocate 
5   Not  using  contraceptives 
12   Participant  unwilling   
2   Medical  condition 
1   In other research 
9   Unable  to  attend  visits 
3   Age 
2   No  ID  book 
58   Did not return for enrolment 
Excluded for ineligibility based on 
pre-enrolment criteria (n=7)   
1  Age ineligibility   
 6   Window-period HIV infection at 
       enrolment   
Excluded (n=2) 
2 No  HIV  test      
Tenofovir 
N=308 
Placebo 
N=141 
Placebo 
N=303 
Tenofovir 
N=137 
Figure 1 Screening, enrolment and randomization of CAPRISA 004 trial participants.
Table 1 HIV prevalence at screening by age group, overall and by site
HIV prevalence
Overall Rural (FP) Urban (STD)
n/N % (95%CI) n/N % (95%CI) n/N % (95%CI)
HIV prevalence 536/2079* 25.8 (23.9-27.7) 272/1081 25.2 (22.6-27.9) 264/998 26.5 (23.8-29.3)
Age specific HIV prevalence
Missing 0/2 0 0/2 0
18 to 24 years 242/1200 20.2 (18.0-22.6) 122/685 17.8 (15.1-20.9) 120/515 23.3 (19.8-27.2)
25 to 29 years 138/465 29.7 (25.6-34.1) 66/209 31.6(25.44-38.4) 72/256 28.1 [22.8-34.1)
30 to 34 years 104/261 39.9 (33.9-46.1) 59/126 46.8 (38.0-55.9) 45/135 33.3 (25.6-42.0)
35 to 40 years 52/151 34.4 (27.0-42.7) 25/61 41.0 (28.8-54.3) 27/90 30.0 (21.0-40.7)
*81 missing observations were excluded from percentage calculations.
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a
Variable Variable category Overall Rural (FP) Urban (STD) P value
N = 889 n = 611 n = 278
Sociodemographic characteristics
Age (Mean; ± SD; range) 23.9; ± 5.1; 18-40 23.3; ± 4.9; 18-40 25.1; ± 5.4;18-39 <0.001
Parity (Mean; ± SD; range) 1.1 (0-8) 1.1 (0-5) 1.4 (0-8) <0.001
Age groups (n, %)
18 to 24 years 579 (65.1) 423 (69.2) 156 (56.1) 0.001
25 to 29 years 177 (19.9) 112 (18.3) 65 (23.4)
30 to 34 years 85 (9.6) 52 (8.5) 33 (11.9)
35 to 40 years 48 (5.4) 24 (3.9) 24 (8.6)
Education level (n, %)
No Schooling 4 (0.4) 4 (0.7) 0 (0) <0.001
Primary school 37 (4.2) 25 (4.1) 12 (4.3)
High school not complete 483 (54.3) 377 (61.7) 106 (38.1)
High school complete 301 (33.9) 195 (31.9) 106 (38.1)
Some Tertiary education 64 (7.2) 10 (1.6) 54 (19.4)
Income level (n, %)
No income 96 (10.9) 78 (12.8) 18 (6.5) <0.001
<R1000 per month 718 (80.7) 526 (86.1) 192 (69.1)
>R1001 per month 75 (8.4) 7 (1.1) 68 (24.5)
Contraception (n, %)
Hormonal injectables 730 (82.1) 508 (83.1) 222 (79.9) 0.58
Hormonal oral 138 (15.5) 89 (14.6) 49 (17.6)
Tubal ligation 20 (2.2) 13 (2.1) 7 (2.5)
Hysterectomy 1 (0.1) 1 (0.2) 0 (0)
Sexual behavioral characteristics
Age at sexual debut (Mean, ± SD, range) 17.4; ± 2.0; 12-26 17.3; ± 2.0; 12-25 17.7; ± 2.0; 12-26 0.01
Total lifetime sex partners (Mean, ± SD, range) 3.3; ± 10.5; 1-202 2.1; ± 1.2; 1-10 6.0; ± 18.4; 1-202 0.001
Sex acts in the past 7 days (Mean, ± SD, range) 2.0; ± 3.0; 0-40 1.7; ± 2.1; 0-28 2.7; ± 4.2;;0-40 <0.001
Sex acts in the past 30 days (Mean, ± SD, range) 8.4; ± 9.1; 0-130 6.7; ± 5.2; 0-40 12.1; ± 13.6;0-130 <0.001
Any anal sex in the past 30 days (n, %) 4 (0.5) 3 (0.5) 1 (0.4) 1.0
One stable sex partner in the past year (n, %) 846 (95.2) 588 (96.2) 258 (92.8) 0.04
One stable sex partner In the past 30 days (n, %) 855 (96.2) 590 (96.6) 265 (95.3) 0.45
Living with regular partner (n, %) 109 (12.3) 58 (9.5) 51 (18.3) <0.001
New sex partner in the last 30 days (n, %) 10 (1.1) 3 (0.5) 7 (2.5) 0.01
More than 2 casual sex partners in the past year (n, %) 38 (4.3) 4 (0.7) 34 (12.2) <0.001
Work requires sleeping overnight away from regular partner (n, %)
b 214 (24.1) 169 (27.7) 45 (16.4) <0.001
Nights sleeping away from partner in the last 30 days (Mean, ± SD, range) 22.4; ± 8.3; 0-30 24.6; ± 5.9; 0-30 17.3; ± 10.5; 0-30 <0.001
Ever forced to have sex with anyone (n, %) 6 (0.7) 1 (0.2) 5 (1.8) 0.01
Ever received money in exchange for sex (n, %) 17 (1.9) 2 (0.3) 15 (5.4) <0.001
Knows sex partner has other sex partners in the last 30 days (n, %) 179 (20.1) 115 (18.8) 64 (23.0) 0.21
Knows sex partner had an HIV test in the last 30 days (n, %) 19 (2.1) 16 (2.6) 3 (1.1) 0.09
Alcohol usually consumed by partner before sex (n, %) 262 (29.5) 162 (26.5) 100 (36.0) 0.01
Alcohol consumed by partner and self before last sex (n, %) 36 (4.0) 4 (0.7) 32 (11.5) <0.001
Male condoms use (n, %)
Always 259 (29.1) 140 (22.9) 119 (42.8) <0.001
Sometimes 482 (54.2) 342 (56.0) 140 (50.4)
Never 148 (16.7) 129 (21.1) 19 (6.8)
Clinical characteristics
Genital symptoms
$ in the last 30 days (n, %)
Any symptoms 335 (37.8) 189 (30.9) 146 (52.5) <0.001
HSV-2 prevalence 454 (51.4)
d 289 (47.6)
c 165 (59.6)
b 0.001
a Parts of the data reported in Table 2 have previously been reported [22]
b1 observation missing
c 4 observations missing
d 5 observations missing - Missing
values were excluded from percentage calculation
$ Genital symptoms of vaginal burning, pruritis, pain after sex, intermenstrual bleeding or burning and
frequency when urinating or abnormal vaginal discharge or genital ulceration.
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in socio-demographic, sexual behaviorial and clinical
characteristics, these characteristics were similar to
those of self-identified sex workers and urban and rural
women in KwaZulu-Natal [11,29]. These pre-trial
cohorts demonstrated HIV incidence rates in excess of
6.0 per 100 women years, making it reasonably easy to
recruit women from specific sites. Importantly the
CAPRISA 004 trial cohort epitomizes the generalized
nature of the HIV epidemic in KwaZulu-Natal, the non-
specific nature of HIV risk and the continued high
HIV incidence rates in these settings with high HIV
prevalence.
While there are clear ethical and scientific imperatives
in undertaking HIV prevention trials in this setting, and
identifying the populations who are still HIV uninfected
but at high risk of getting infected, declines in incidence
rates over time may lead to futile results [21]. Given the
high incidence rates observed in young rural FP and
urban STD women in the pretrial cohorts, the strategic
selection, recruitment and inclusion of young women
who are at high risk of HIV acquisition in HIV preven-
tion trials is justified [11].
The diversity of sample population selected for the
CAPRISA 004 trial results with young rural FP women
with low coital frequency but social instability resulting
from partner’s being migrant workers on one hand and on
the other hand, the slightly older urban STD cohort, more
likely to have multiple partners, higher coital frequency
and more sexually transmitted infections provides valuable
safety assessment information in relation to timing and
frequency of product use. Furthermore, assessing safety
and effectiveness in cohorts at high risk of acquiring HIV
but with varying risk factors including coital frequency,
partner characteristics, risk of sexually transmitted infec-
tions, condom use patterns and study product use pro-
vides an optimal combination of circumstances and
populations where study product will be used. The few
years of education, limited employment opportunities and
low income even if employed, force women to have men
in their lives to ensure their survival. Awareness of partner
HIV status including HIV risk behaviors and its implica-
tions for personal risk is understood but ability to negoti-
ate mutually faithful monogamy and condom use remains
limited. Whilst coerced sex was uncommon, the overall
male condom use reporting rate of 29.1% is indicative of
women’s self report to study staff in the context of HIV
risk-reduction counseling. However, measurement of male
condom use is important, though social incohesion is an
important factor contributing to the rapid spread of HIV
in urban and rural settings in South Africa.
Whilst a key limitation of this study is the sample popula-
tions selected which may limit generalizability, a sector of
women at high risk of acquiring HIV infection is
represented. These urban STD and rural FP women enrolled
in the CAPRISA 004 trial, equally randomized to receive
study product and placebo, together with the HIV specific
nature of the product being tested, namely 1% tenofovir gel
is an optimal combination to maximize outcomes in a proof
of concept trial. However, to increase representativeness,
female sex workers, and females injecting drugs users and
young women from the general population must be
included in HIV prevention intervention trials.
Conclusion
The baseline characteristics of enrolled rural FP and
urban STD women differ significantly. The frequent and
infrequent gel use based on coital activity would advance
our knowledge on the safety and effectiveness of 1%
tenofovir gel for male to female sexual transmission of
HIV. The role of microbicides in this setting is critical to
ensure the right of women to remain HIV uninfected
which is key to altering HIV epidemic trajectory.
Abbreviations
CAPRISA: Centre for the AIDS Programme of Research in South Africa; CAT:
CAPRISA AIDS Treatment; CI: Confidence Interval; FHI: Family Health
International; FP: Family Planning; HEC: Hydroxy-ethylcellulose; HIV: Human
Immunodeficiency virus; HSV-2: herpes simplex virus type-2; PCR: Polymerase
chain reaction; RNA: Ribonucleic acid; SD: Standard deviation; STD: Sexually
transmitted disease.
Acknowledgements
The CAPRISA 004 trial is supported by the Centre for the AIDS Programme
of Research in South Africa (CAPRISA), the United States Agency for
International Development (USAID), FHI (co operative agreement # GPO-A-
00-05-00022-00, contract # 132119), and LIFElab, now TIA (Technology
Innovation Agency) a biotechnology centre of the South African
Department of Science and Technology. Support from CONRAD for the
product manufacturing and packaging as well as support from Gilead
Sciences for the Tenofovir used in the production of gel is gratefully
acknowledged. We acknowledge the Columbia University-Southern African
Fogarty AIDS International Training and Research Programme (CU-SA AITRP),
funded by the Fogarty International Center, National Institutes of Health
(grant# D43TW00231), for supporting the training of clinical trial staff.
This study would not have been possible without the support of the
women participating in this trial and their contributions and commitment is
acknowledged with deep appreciation. Special thanks to members of the
CAPRISA Research Support Group members at the CAPRISA Vulindlela and
eThekwini Clinical Research Sites. We acknowledge the dedication and
commitment of staff at the CAPRISA eThekwini and Vulindlela Clinical
Research Sites in implementing this trial; the CAPRISA Research Laboratory
staff for undertaking the laboratory testing and archiving of samples;
CAPRISA Data Management and Statistics staff for management and quality
assurance of case report forms. The funding agencies played no role in the
design and conduct of the trial, analysis and interpretation of the data or
decision to publish.
The CAPRISA 004 Trial Group includes (in alphabetical order)
Principal Investigators: Q. Abdool Karim and S. S. Abdool Karim
Site Directors: J. A. Frohlich, A. B. M. Kharsany, and K. P. Mlisana
Project Coordinators: C. Baxter and L. E. Mansoor
Site Coordinators: N. A. Arulappan and S. Maarschalk
Assistant Site Coordinators: H. Humphries, G. Parker, J. Richards, and J. Upton
Study Gynecologist: S. Sibeko
Clinicians: B. Mdluli, N. Miya, L. Mtongana, N. Naicker, Z. Omar, and D. Sokal (FHI)
Nurses: D. D. Chetty, F. Dlamini, S. D. Gumede, Z. Gumede, N. E. Khambule, N.
Langa, B. T. Madlala, N. Madlala, N. Mkhize, Z. L. Mkhize, M. Mlotshwa, C.
Ndimande, N. Ngcobo, C. Ntshingila, B. Phungula, and T. E. Vumase
Karim et al. Trials 2011, 12:67
http://www.trialsjournal.com/content/12/1/67
Page 6 of 8Counselors: N. B. Biyela, N. Dladla, T. Dlamini, C. T. Khwela, N. Mayisela, M. R.
Mlaba, J. Mchunu, Z. Msimango, D. Nkosi, and T. Shange
Pharmacists: L. Chelini, T. N. Gengiah, A. Gray, B. Maharaj, G. I. Masinga, A.
Naidoo, and M. Upfold
Pharmacist’s Assistants: B. Moodley, Y. Naidoo, C. Ngcobo, T. Nzimande, and
L. Zondi
Statisticians: A. C. Grobler, D. Taylor (FHI), L. Werner, and N. Yende
Data Management: R. Lallbahadur, M. Mdladla, K. Naidoo, T. Nala, C. Pillay, P.
Sikakane, and T. Zondo
Quality Assurance: T. Govender, N. Mvandaba, F. van Loggerenberg, and I.
van Middelkoop
Laboratory: J. Naicker, V. Naranbhai, N. Ndlovu, N. Samsunder, S. Sidhoo, P.
Tshabalala, J. Ledwaba (NICD), and L. Morris (NICD)
Behavioral Science: J. Fisher (University of Connecticut) and K. MacQueen (FHI)
Cohort Coordinators: L. R. Luthuli and F. Ntombela
Cohort Administrators: P. F. Chonco, D. P. Magagula, P. C. Majola, T. Ndlovu, L.
Ngobese, N. Ngubane, and N. M. Zwane
Community Outreach: N. Bhengu, P. Buthelezi, P. D. Lembethe, B. F.
Mazibuko, S. F. Mdluli, W. N. Mkhize, S. P. Ndlovu, S. Ngubane, R. M. Ogle,
and R. B. Xulu
Administrative Staff: N. Amla, S. A. Barnabas, T. Malembe, M. Matthews, Y. T.
Miya, A. Mqadi, S. Panday, S. Sibisi, M. Swart, and B. Zulu.
Author details
1Centre for the AIDS Programme of Research in South Africa (CAPRISA),
Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban,
South Africa.
2Mailman School of Public Health, Department of
Epidemiology, Columbia University, New York, USA.
Authors’ contributions
QAK and SSAK as Co-Principal Investigators conceived and designed the
trial, oversight and implementation of the trial; responsible for critical edits
and final approval of the manuscript. ABMK contributed to the analysis,
drafting and writing the manuscript. NY contributed to the analysis and
critical edits to the manuscript. AG as the trial statistician contributed to the
design and statistical framework. CB and LEM contributed to study oversight
and critical edits to the manuscript. JAF, KM, SM, NA, SS, ZO, MM, TNG, NS
contributed to the site implementation of the trial, oversight, quality
assurance and critical review of the manuscript. All authors have read and
approved the final manuscript.
Competing interests
Quarraisha Abdool Karim is the Co-Principal investigator of the HPTN
Prevention Leadership Group (NIH/NIAID U01 AI068619) and Salim S Abdool
Karim is the Protocol Chair of the HPTN 035 trial which was supported by
the National Institutes of Health (grant # U01AI46749 and U01AI068633). All
other authors declare that they have no competing interests.
Received: 14 November 2010 Accepted: 7 March 2011
Published: 7 March 2011
References
1. Abdool Karim SS, Churchyard GJ, Abdool Karim Q, Lawn SD: HIV infection
and tuberculosis in South Africa: an urgent need to escalate the public
health response. Lancet 2009, 374:921-933.
2. UNAIDS World Health Organization: AIDS epidemic update: November
2009. 2009, “UNAIDS/09.36E/JC1700E”. ISBN 978 92 9173 832 8 (NLM
classification: WC 503.41).
3. Pettifor AE, Rees HV, Kleinschmidt I, Steffenson AE, MacPhail C, Hlongwa-
Madikizela L, et al: Young people’s sexual health in South Africa: HIV
prevalence and sexual behaviors from a nationally representative
household survey. AIDS 2005, 19:1525-1534.
4. Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, et al:
South African national HIV prevalence, incidence, behaviour and
communication survey 2008: A turning tide among teenagers? Cape
Town: HSRC Press; 2009.
5. Barnighausen T, Tanser F, Gqwede Z, Mbizana C, Herbst K, Newell ML: High
HIV incidence in a community with high HIV prevalence in rural South
Africa: findings from a prospective population-based study. AIDS 2008,
22:139-144.
6. Pettifor A, Macphail C, Rees H, Cohen M: HIV and sexual behavior among
young people: the South African paradox. Sex Transm Dis 2008,
35:843-844.
7. Cowan F, Pettifor A: HIV in adolescents in sub-Saharan Africa. Curr Opin
HIV AIDS 2009, 4:288-293.
8. Quinn TC, Overbaugh J: HIV/AIDS in women: an expanding epidemic.
Science 2005, 308:1582-1583.
9. Frohlich JA, Kharsany ABM, Carrara H, Makhaye GM, Abdool Karim SS,
Abdool Karim Q: Temporal Trends in HIV infection in Rural South Africa:
Implications for HIV Prevention Research. XV INTERNATIONAL AIDS
CONFERENCE BANGKOK 11-16 JULY 2004 Abstract number MoPpC2013 2004.
10. Ramjee G, Kapiga S, Weiss S, Peterson L, Leburg C, Kelly C, et al: The value
of site preparedness studies for future implementation of phase 2/IIb/III
HIV prevention trials: experience from the HPTN 055 study. J Acquir
Immune Defic Syndr 2008, 47:93-100.
11. Abdool Karim Q, Kharsany A, Frohlich J, Werner L, Mashego M, Mlotshwa M,
et al: Stabilizing HIV prevalence masks high HIV incidence rates amongst
rural and urban women in KwaZulu-Natal, South Africa. International
Journal of Epidemiology 2010.
12. Collins C, Coates TJ, Curran J: Moving beyond the alphabet soup of HIV
prevention. AIDS 2008, 22(Suppl 2):S5-8.
13. Padian NS, Buve A, Balkus J, Serwadda D, Cates W Jr: Biomedical
interventions to prevent HIV infection: evidence, challenges, and way
forward. Lancet 2008, 372:585-599.
14. Coates TJ, Richter L, Caceres C: Behavioural strategies to reduce HIV
transmission: how to make them work better. Lancet 2008, 372:669-684.
15. Feldblum PJ, Adeiga A, Bakare R, Wevill S, Lendvay A, Obadaki F, et al:
SAVVY vaginal gel (C31G) for prevention of HIV infection: a randomized
controlled trial in Nigeria. PLoS One 2008, 3:e1474.
16. Peterson L, Nanda K, Opoku BK, Ampofo WK, Owusu-Amoako M,
Boakye AY, et al: SAVVY (C31G) gel for prevention of HIV infection in
women: a Phase 3, double-blind, randomized, placebo-controlled trial in
Ghana. PLoS One 2007, 2:e1312.
17. Skoler-Karpoff S, Ramjee G, Ahmed K, Altini L, Plagianos MG, Friedland B,
et al: Efficacy of Carraguard for prevention of HIV infection in women in
South Africa: a randomised, double-blind, placebo-controlled trial. Lancet
2008, 372:1977-1987.
18. Van Damme L, Govinden R, Mirembe FM, Guedou F, Solomon S, Becker ML,
et al: Lack of effectiveness of cellulose sulfate gel for the prevention of
vaginal HIV transmission. N Engl J Med 2008, 359:463-472.
19. Van Damme L, Ramjee G, Alary M, Vuylsteke B, Chandeying V, Rees H, et al:
Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1
transmission in female sex workers: a randomised controlled trial. Lancet
2002, 360:971-977.
20. Abdool Karim S, Coletti A, Richardson B, Ramjee G, Hoffman I, Chirenje M,
et al: Safety and effectiveness of vaginal microbicides buffer gel and
0.5% PRO 2000/5 gel for the prevention of HIV Infection in women:
results of the HPTN 035 trial. Montreal, Canada; 2009, Oral Abstract 48LB,
16th Conference on Retroviruses and Opportunistic Infections.
21. IOM (Institute of Medicine): Methodological challenges in biomedical HIV
prevention trials. Washington, DC: The National Academies Press; 2008.
22. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C,
Mansoor LE, et al: Effectiveness and safety of tenofovir gel, an
antiretroviral microbicide, for the prevention of HIV infection in women.
Science 2010, 329:1168-1174.
23. MacQueen KM, Karim QA: Practice brief: adolescents and HIV clinical
trials: ethics, culture, and context. J Assoc Nurses AIDS Care 2007, 18:78-82.
24. Cockcroft D, Gault M: Prediction of creatinine clearance from serum
creatinine. Nephron 1976, 16:31-41.
25. Kharsany AB, Hancock N, Frohlich JA, Humphries HR, Abdool Karim SS,
Abdool Karim Q: Screening for ‘window-period’ acute HIV infection
among pregnant women in rural South Africa. HIV Med 2010, 11:661-665.
26. Abdool Karim Q, Kharsany ABM, Naidoo K, Yende N, Gengiah T, Omar Z,
et al: Co-enrollment in multiple HIV prevention trials: Experiences from
the CAPRISA 004 Tenofovir gel trial. Contemp Clin Trials 2011.
27. International Conference on Harmonisation guidelines E9: International
Conference on Harmonisation of technical requirements for registration
of pharmaceuticals for human use. ICH harmonised tripartate guideline
statistical principles for clinical trials-E9. 1998.
28. Welz T, Hosegood V, Jaffar S, Batzing-Feigenbaum J, Herbst K, Newell ML:
Continued very high prevalence of HIV infection in rural KwaZulu-Natal,
Karim et al. Trials 2011, 12:67
http://www.trialsjournal.com/content/12/1/67
Page 7 of 8South Africa: a population-based longitudinal study. AIDS 2007,
21:1467-1472.
29. van Loggerenberg F, Mlisana K, Williamson C, Auld SC, Morris L, Gray CM,
et al: Establishing a cohort at high risk of HIV infection in South Africa:
challenges and experiences of the CAPRISA 002 acute infection study.
PLoS One 2008, 3:e1954.
doi:10.1186/1745-6215-12-67
Cite this article as: Karim et al.: Recruitment of high risk women for HIV
prevention trials: baseline HIV prevalence and sexual behavior in the
CAPRISA 004 tenofovir gel trial. Trials 2011 12:67.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Karim et al. Trials 2011, 12:67
http://www.trialsjournal.com/content/12/1/67
Page 8 of 8